
ImmuCell (NASDAQ:ICCC) reported a record first quarter of 2026, with management saying the company’s narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales.
President and Chief Executive Officer Olivier te Boekhorst said the company is beginning to see results from strategic changes made in 2025, including a sharper focus on the calf scours market, leadership investments and manufacturing yield improvements.